Patents by Inventor Donald Metcalf

Donald Metcalf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080274973
    Abstract: The present invention relates generally to a novel haemopoietin receptor or components or parts thereof and to genetic sequences encoding same. The receptor molecules and their components and/or parts and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.
    Type: Application
    Filed: July 1, 2008
    Publication date: November 6, 2008
    Inventors: Tracy Willson, Nicos A. Nicola, Douglas J. Hilton, Donald Metcalf, Jian Guo Zhang
  • Publication number: 20080166730
    Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction. The molecules of the present invention are useful, therefore, in modulating cellular responsiveness to cytokines as well as other mediators of signal transduction such as endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites.
    Type: Application
    Filed: October 23, 2007
    Publication date: July 10, 2008
    Applicant: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Douglas J. Hilton, Warren S. Alexander, Elizabeth M. Viney, Tracy A. Willson, Rachael T. Richardson, Robyn Starr, Sandra E. Nicholson, Donald Metcalf, Nicos A. Nicola
  • Patent number: 7279557
    Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction. The molecules of the present invention are useful, therefore, in modulating cellular responsiveness to cytokines as well as other mediators of signal transduction such as endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites.
    Type: Grant
    Filed: November 17, 2004
    Date of Patent: October 9, 2007
    Assignee: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Douglas J. Hilton, Warren S. Alexander, Elizabeth M. Viney, Tracy A. Willson, Rachael T. Richardson, Robyn Starr, Sandra E. Nicholson, Donald Metcalf, Nicos A. Nicola
  • Publication number: 20060242718
    Abstract: The present invention relates generally to amino acid sequences obtainable from SOCS proteins and which are capable of interacting with intracellular molecules. The present invention further relates to nucleic acid molecules encoding said amino acid sequences. The amino acid sequences and the nucleic acid molecules encoding same of the present invention are useful in modulating degradation of proteinaceous molecules such as but not limited to SOCS proteins and proteinaceous molecules associate therewith. The present invention provides a mechanism for modulating cytokine or cytokine-like molecule signaling by modulating the degradation of activated signal transduction molecules or their negative regulators, i.e. the SOCS proteins.
    Type: Application
    Filed: April 10, 2006
    Publication date: October 26, 2006
    Inventors: Tracy Willson, Richard Simpson, Alison Farley, Sandra Nicholson, Jian Zhang, Manuel Baca, Nicos Nicola, Douglas Hilton, Warren Alexander, Donald Metcalf
  • Patent number: 7078174
    Abstract: The present invention relates generally to amino acid sequences obtainable from SOCS proteins and which are capable of interacting with intracellular molecules. The present invention further relates to nucleic acid molecules encoding said amino acid sequences. The amino acid sequences and the nucleic acid molecules encoding same of the present invention are useful in modulating degradation of proteinaceous molecules such as but not limited to SOCS proteins and proteinaceous molecules associated therewith. The present invention provides a mechanism for modulating cytokine or cytokine-like molecule signalling by modulating the degradation of activated signal transduction molecules or their negative regulators, i.e. the SOCS proteins.
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: July 18, 2006
    Assignee: The Walter & Eliza Hall Institute of Medical Research
    Inventors: Tracy Ann Willson, Richard John Simpson, Alison Mary Farley, Sandra Elaine Nicholson, Jian-Guo Zhang, Manuel Baca, Nicos A. Nicola, Douglas J. Hilton, Warren Scott Alexander, Donald Metcalf
  • Patent number: 7049418
    Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction. The molecules of the present invention are useful, therefore, in modulating cellular responsiveness to cytokines as well as other mediators of signal transduction such as endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites.
    Type: Grant
    Filed: July 19, 2001
    Date of Patent: May 23, 2006
    Assignee: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Douglas J. Hilton, Warren S. Alexander, Elizabeth M. Viney, Tracy A. Willson, Rachael T. Richardson, Robyn Starr, Sandra E. Nicholson, Donald Metcalf, Nicos A. Nicola
  • Publication number: 20060093604
    Abstract: The present invention relates generally to a method for treating or preventing or otherwise ameliorating the effects of inflammatory conditions such as but not limited to chronic immune-mediated inflammatory diseases. The present invention further provides pharmaceutical compositions comprising agents which inhibit one or more inflammatory cytokines and/or which down-regulate expression of genes which encode inflammatory cytokines. Such compositions are useful in the treatment and prophylaxis of inflammatory conditions such as inflammatory arthritis amongst other chronic immune-mediated inflammatory diseases. The present invention further provides an animal model for studying the kinetics of and/or screening for agents useful in the treatment or prophylaxis of inflammatory conditions.
    Type: Application
    Filed: August 22, 2003
    Publication date: May 4, 2006
    Applicant: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Kathryn Lawlor, Ian Wicks, Ian Campell, Andrew Roberts, Donald Metcalf
  • Publication number: 20060069023
    Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of conditions arising from or otherwise associated with aberrations in hormone signalling. The present invention further provides an animal model useful for screening for agents capable of agonizing or antagonizing hormone signalling. More particularly, the present invention contemplates a method for the treatment and/or prophylaxis of conditions arising from or otherwise associated with aberrations in growth hormone signalling. The present invention further comprises a genetically modified animal. More particularly, the animals are genetically modified such that they have altered growth hormone signalling. The genetically modified animals of the present invention range from laboratory animals useful inter alia for animal models for studying hormone regulation and for the development of therapeutic protocols predicated, in part, on modulating hormone signalling to livestock animals.
    Type: Application
    Filed: September 19, 2005
    Publication date: March 30, 2006
    Inventors: Warren Alexander, Donald Metcalf, Christopher Greenhalgh
  • Publication number: 20060003377
    Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction. The molecules of the present invention are useful, therefore, in modulating cellular responsiveness to cytokines as well as other mediators of signal transduction such as endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites.
    Type: Application
    Filed: August 29, 2005
    Publication date: January 5, 2006
    Applicant: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Douglas Hilton, Warren Alexander, Elizabeth Viney, Tracy Willson, Rachael Richardson, Robyn Starr, Sandra Nicholson, Donald Metcalf, Nicos Nicola
  • Publication number: 20050208521
    Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction. The molecules of the present invention are useful, therefore, in modulating cellular responsiveness to cytokines as well as other mediators of signal transduction such as endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites.
    Type: Application
    Filed: November 17, 2004
    Publication date: September 22, 2005
    Inventors: Douglas Hilton, Warren Alexander, Elizabeth Viney, Tracy Willson, Rachael Richardson, Robyn Starr, Sandra Nicholson, Donald Metcalf, Nicos Nicola
  • Patent number: 6911530
    Abstract: The present invention relates generally to a novel haemopoietin receptor or components or part thereof and to genetic sequences encoding same. The receptor molecules and their components and/or parts and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: June 28, 2005
    Assignee: Amrad Operations, Pty., Ltd.
    Inventors: Tracy Willson, Nicos A. Nicola, Douglas J. Hilton, Donald Metcalf, Jian Guo Zhang
  • Patent number: 6905842
    Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction. The molecules of the present invention are useful, therefore, in modulating cellular responsiveness to cytokines as well as other mediators of signal transduction such as endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites.
    Type: Grant
    Filed: October 31, 1997
    Date of Patent: June 14, 2005
    Assignee: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Douglas J. Hilton, Warren S. Alexander, Elizabeth M. Viney, Tracy A. Willson, Rachael T. Richardson, Robyn Starr, Sandra E. Nicholson, Donald Metcalf, Nicos A. Nicola
  • Patent number: 6870031
    Abstract: The present invention is directed to a novel haemopoietin receptor or a derivative thereof and to genetic sequences encoding same. The receptor molecule and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor. The present invention particularly relates to a receptor for leptin.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: March 22, 2005
    Assignee: Amrad Operations Pty. Ltd.
    Inventors: Douglas James Hilton, Tracy Willson, Timothy Gainsford, Warren S Alexander, Donald Metcalf, Ashley Ng, Nicos A Nicola
  • Publication number: 20050004015
    Abstract: The present invention is directed to a novel haemopoietin receptor or a derivative thereof and to genetic sequences encoding same. The receptor molecule and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor. The present invention particularly relates to a receptor for leptin.
    Type: Application
    Filed: December 7, 2001
    Publication date: January 6, 2005
    Inventors: Douglas Hilton, Tracy Willson, Timothy Gainsford, Warren Alexander, Donald Metcalf, Ashley Ng, Nicos Nicola
  • Publication number: 20030004098
    Abstract: The present invention provides isolated DNA molecules encoding human and murine LIF and methods of producing LIF by the expression of the isolated DNA in suitable host cells. The invention further provides human and murine LIF polypeptides, pharmaceutical compositions containing LIF, and methods of use thereof.
    Type: Application
    Filed: February 12, 2001
    Publication date: January 2, 2003
    Inventors: David Paul Gearing, Nicholas Martin Gough, Douglas James Hilton, Julie Ann King, Donald Metcalf, Edouard Collins Nice, Nicos Anthony Nicola, Richard John Simpson, Tracy Ann Willson
  • Publication number: 20020147307
    Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction.
    Type: Application
    Filed: July 19, 2001
    Publication date: October 10, 2002
    Inventors: Douglas J. Hilton, Warren S. Alexander, Elizabeth M. Viney, Tracy A. Willson, Rachael T. Richardson, Robyn Starr, Sandra E. Nicholson, Donald Metcalf, Nicos A. Nicola
  • Publication number: 20020090682
    Abstract: The present invention relates generally to a novel haemopoietin receptor or components or parts thereof and to genetic sequences encoding same. The receptor molecules and their components and/or parts and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.
    Type: Application
    Filed: November 7, 2001
    Publication date: July 11, 2002
    Inventors: Tracy Willson, Nicos A. Nicola, Douglas J. Hilton, Donald Metcalf, Jian Guo Zhang
  • Patent number: 6414128
    Abstract: The present invention is directed to a novel haemopoietin receptor or a derivative thereof and to genetic sequences encoding same. The receptor molecule and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor. The present invention particularly relates to a receptor for leptin.
    Type: Grant
    Filed: September 17, 1998
    Date of Patent: July 2, 2002
    Assignee: Amrad Operations Pty. Ltd.
    Inventors: Douglas James Hilton, Tracy Willson, Timothy Gainsford, Warren S Alexander, Donald Metcalf, Ashley Ng, Nicos A Nicola
  • Patent number: 6387875
    Abstract: The present invention relates to a isolated leukaemia inhibitory factor (LIF)-binding protein (LBP) in soluble form and obtainable from a first mammalian species, said LBP capable of inhibiting the ability of LIF from a second mammalian species to induce differentiation of M1 myeloid leukaemic cells in vitro to a greater extent when compared to its ability to inhibit LIF from said first mammalian species.
    Type: Grant
    Filed: November 10, 1994
    Date of Patent: May 14, 2002
    Assignee: Amrad Corporation Limited
    Inventors: Nicos Anthony Nicola, Meredith Layton, Donald Metcalf, Richard J Simpson
  • Publication number: 20020045741
    Abstract: The present invention relates generally to a novel haemopoietin receptor or derivatives thereof and to genetic sequences encoding same. Interaction between the novel receptor of the present invention and a cytokine ligand facilitates proliferation, differentiation and survival of a wide variety of cells. The novel receptor and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.
    Type: Application
    Filed: March 10, 1998
    Publication date: April 18, 2002
    Inventors: TRACY WILLSON, NICOS A. NICOLA, DOUGLAS J. HILTON, DONALD METCALF, JIAN GUO ZHANG